Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Oncologic Safety and Efficacy of Cell-Assisted Lipotransfer for Breast Reconstruction in a Murine Model of Residual Breast Cancer.

Jin X., Huang Y., Yoo HK., Lee SY., Chun YS., Hong KY.

Animal Study on Facial Rejuvenation, published in Aesthetic Plast Surg (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Aesthetic Plast Surg (2022)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
35918436
DOI
10.1007/s00266-022-03021-3
Citations
4

Abstract (original English)

Cell-assisted lipotransfer (CAL) is a novel technique for fat grafting that combines the grafting of autologous fat and adipose-derived stromal cells (ASCs) to enhance fat graft retention; however, its oncologic safety is controversial. Herein, we investigated the oncologic safety of CAL for breast reconstruction using a murine model of residual breast cancer. Various concentrations of 4T1 cells (murine breast cancer cells) were injected into female mastectomized BALB/c mice to determine the appropriate concentration for injection. One week after injection, mice were divided into control (100 μL fat), low CAL (2.5 × 10 5 ASCs/100 μL fat), and high CAL (1.0 × 10 6 ASCs/100 μL fat) groups, and fat grafting was performed. The injection of 5.0 × 10 3 4T1 cells was appropriate to produce a murine model of residual breast cancer. The weight of the fat tumor mass was significantly higher in the high CAL group than in the other groups (p < 0.05). However, the estimated tumor weight was not significantly different between the groups. Additionally, the fat graft survival rate was significantly higher in the high CAL group than in the control and low CAL groups (p < 0.05). No significant difference was noted in the percentage of Ki-67-positive cells, suggesting that tumor proliferation was not significantly different between the groups. In summary, CAL significantly improved fat graft sur

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
FemaleAnimalsMiceAdipose TissueDisease Models, AnimalAdipocytesMammaplastyNeoplasms

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research